Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference109 articles.
1. The first 12 months of COVID-19: a timeline of immunological insights
2. World Health Organization . Coronavirus disease (COVID-19) pandemic. www.who.int/emergencies/diseases/novel-coronavirus-2019 Date last updated: 14 September 2022. Date last updated: 15 September 2022.
3. World Health Organization . Therapeutics and COVID-19: living guideline. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5 Date last updated: 16 September 2022. Date last accessed: 4 November 2022.
4. Our World in Data . Coronavirus (COVID-19) vaccinations. https://ourworldindata.org/covid-vaccinations Date last updated: 28 October 2022. Date last accessed: 4 November 2022.
5. Viruses and bacteria in acute asthma exacerbations - A GA2LEN-DARE* systematic review
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献